Peptide research, scientific progress and industry news, explained clearly.
Explore new findings, understand the evidence and follow the developments shaping peptide science.
Buy 1, Get 1 20% Off
Pick any two research compounds. Take 20% off the lower priced one.
Applied automatically at checkout, no code needed
Claim my 20% off →In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.
AI generated editorial illustration of an exercise science room, not a photograph of the T-REx trial site.
In a 40 week randomized trial, resistance exercise improved strength and reduced lean tissue loss during tirzepatide treatment, despite similar weight loss.
AI generated editorial illustration of an NMR laboratory, not a photograph of a particular facility or a verified instrument model.
NMR connects peptide signals to local chemical environments and spatial constraints. Learn why structural models, ensembles and purity measurements differ.
AI generated conceptual illustration of a wet ribbon, not elastin itself, a molecular structure or the computational study’s apparatus.
A new elastin simulation separates water and protein entropy. Why hydration helps explain recoil, and how the fragment model builds on experiments.
AI generated illustration of an optical cuvette and laboratory instrument, not a photograph of a specific experiment or a verified instrument model.
Circular dichroism helps estimate peptide secondary structure. Learn what helix and sheet signals mean, why reference data matter, and what a curve cannot reveal.
AI-generated conceptual editorial illustration of antibody and peptide teaching props, not an argenx or UNP facility or validated molecular structures.
Argenx agrees to acquire Unnatural Products. What its macrocyclic peptide platform adds to antibody discovery, and how the proposed deal builds on their collaboration.
AI-generated conceptual editorial illustration of three receptor teaching props, not actual receptor or retatrutide structures or a clinical trial scene.
Retatrutide is Lilly’s investigational triple receptor agonist. Understand its mechanism, TRIUMPH and TRANSCEND trials, comparisons and current approval status.
AI-generated editorial illustration of a gas-responsive gel concept, not a photograph of the experiment or a validated apparatus.
Short peptide coatings make gold nanoparticles respond to CO2. A new study carries their color change into hydrogels that can be patterned and reset.
AI-generated editorial illustration of a conceptual teaching model, not an experimentally resolved molecular structure or a depiction of the two-chain study model.
Peptide stapling joins selected positions with a chemical bridge. Learn how placement, linker length and the target-facing surface shape a useful peptide helix.
AI generated editorial illustration, not the study apparatus or a validated instrument design.
A new direct infusion method compared 275 antibody samples in about 12 hours. How faster peptide mapping works and where it fits in research.
AI generated editorial illustration of synthesis equipment, not the cited experiments or a validated apparatus.
Solid phase peptide synthesis builds chains on a resin. Follow the coupling cycle, understand missing residues, and see why purification comes afterward.
AI generated editorial illustration, not a photograph of the trial or a validated anatomical model.
The TRIUMPH 4 trial found about two points more knee pain improvement with retatrutide than placebo at 68 weeks. What the ACR abstract shows.
AI generated editorial illustration of microscopy equipment, not the study apparatus or a validated instrument design.
Peptide self assembly links short amino acid chains into ordered fibers and hydrogels. A honeycomb study reveals how sequence controls water channels.
AI-generated editorial illustration of a desk where advertising copy is reviewed, not a photograph of the cited decision or of any company office.
An advertising review panel told Good Life Meds to drop personalized and health benefit claims for its compounded Tirzepatide+ product. What the record shows.
AI-generated editorial illustration of a clinical laboratory bench, not a photograph of a named laboratory, instrument or study result.
Two small human studies, a failed endpoint and a two-death safety file. What the evidence for ipamorelin supports, and why the new HHS policy does not cover it.
AI-generated editorial illustration of laboratory work, not a photograph of a named facility or an event in this report.
ASHP acknowledged safeguards in the HHS peptide compounding policy. Earlier letters and a petition show why evidence and enforcement remain disputed.
AI-generated editorial illustration of a vial on an evidence bag, not a photograph of the tested samples or a validated instrument design.
Reported retatrutide vial tests found an apparent identity mismatch, bacteria and label-amount discrepancies. Each finding answers a different question.
Amino acid chains, the size boundary with proteins, laboratory synthesis and what analytical tests can establish. A sourced introduction to peptide chemistry.
Check research solution concentration, portion volume and portions per vial. Includes a worked example and the limits of the calculation.
AI-generated editorial illustration of a courthouse exterior, not a photograph of the Coroners Court of Victoria.
A Victorian coroner found the actor died of anaphylaxis after injecting a prescribed CJC1295 and ipamorelin blend, and asked Australia's regulator to consider a Schedule 10 ban.
AI-generated editorial illustration of a clinical research day room, not a photograph of a trial site.
After a single 1 mg semaglutide dose, vomiting hit 43.0% of people on tradipitant and 58.5% on placebo. The data come from Vanda's release, and the pill is approved only for motion sickness.
AI-generated editorial illustration of a diabetes clinic consultation desk, not a photograph of a trial site.
In 1,298 adults with type 2 diabetes, retatrutide cut A1C by 2.2 points and body weight by about 20% at 80 weeks. Ozempic 2 mg produced 1.8 points and 9.4%. Retatrutide is not approved.
AI-generated editorial illustration of a microbiology bench, not a photograph of the cited experiment.
Researchers screened 116 antimicrobial peptides from African wildlife and shortened a scorpion venom peptide to 16 residues. New work explains how it breaks Gram-negative membranes and why the 8-residue version failed.
AI-generated editorial illustration of a compounding pharmacy workspace, not a photograph of a named facility.
HHS filed a policy on October 28, 2026 that lets licensed pharmacies and physicians compound six peptides without federal enforcement action. Research-use-only sellers are not covered.
AI-generated editorial illustration of sleep study monitoring equipment, not a photograph of a trial site.
Two Phase 3 trials cut the apnea-hypopnea index at 80 weeks in obstructive sleep apnea. The published paper reports two different sets of results and explains why.
AI-generated editorial illustration of microscopy equipment, not a photograph of the cited experiments or a validated instrument design.
A fluorescent tag can change peptide membrane binding, shape and distribution. Three studies explain why a brighter signal needs a chemical check.
AI-generated editorial illustration of laboratory samples, not a photograph or result of the cited experiments.
Scrambling preserves amino acid composition, but can change assembly and cell responses. Three experiments show what a useful negative control must establish.
AI-generated editorial illustration of immune assay equipment, not a photograph of AMPLIFY-7P or a validated instrument design.
ELI-002 7P missed its primary pancreatic cancer trial endpoint. The ESMO analysis explains the ctDNA subgroup signal, immune responses and Phase 3 questions.
AI-generated editorial illustration of peptide synthesis materials, not a photograph of the cited experiments or a validated synthesis setup.
N-terminal acetylation and C-terminal amidation change peptide charge and recognition. Studies show why greater stability does not guarantee greater activity.
AI-generated editorial illustration of a fictional Gilead campus sign, not a photograph of the event or an actual Gilead facility.
Gilead agreed to pay $1.275 billion upfront at closing for HCXT-2001. What the oral IL-23 receptor peptide adds, and how it differs from emvistegrast.
AI-generated editorial illustration of mass spectrometry equipment, not a photograph of the cited experiments or a validated instrument design.
Leucine and isoleucine have the same exact mass. How specialized peptide fragmentation can distinguish them, and why a mass match leaves sequence ambiguity.
AI-generated editorial illustration of peptide library screening equipment, not a photograph of the cited studies or a validated apparatus.
How researchers build and decode cyclic peptide libraries, what a 15,217-member proteome study found, and why a binding hit still needs validation.
AI-generated editorial illustration of cell imaging equipment, not a photograph of the cited experiments or a validated instrument design.
Binding affinity cannot explain how a cell responds over time. GLP-1 receptor experiments separate desensitization, internalization and recycling.
AI-generated editorial illustration of a generic pathology concept, not a photograph of ANTHEM-UC or an actual trial facility.
ANTHEM-UC followup found remission at 76 weeks among selected responders. How the extension differs from icotrokinra’s randomized ulcerative colitis trial.
AI-generated editorial illustration of generic analytical hardware, not a photograph of the cited experiments or a validated instrument design.
Ion suppression can weaken peptide LC-MS signals. How matrix effects, sample recovery and isotope standards change the meaning of a chromatographic peak.
AI-generated editorial illustration of a generic pharmacokinetics laboratory, not an Ascletis facility or study photograph. Instrument design is not validated; screen data are illustrative.
Ascletis says oral amylin ASC36o is in US Phase 1. Why its forthcoming human pharmacokinetic data matter more than animal exposure claims.
AI-generated editorial illustration of fluorescence microscopy, not a photograph of the cited experiments or a validated instrument design. Screen signals are illustrative.
A fluorescent cell can hold peptides in endosomes without delivering them to intracellular targets. What CAPA and SLEEQ experiments actually measure.
AI-generated editorial illustration of liver-assessment equipment, not a photograph of the IMPACT trial or an actual clinical facility.
Altimmune plans a 48-week pemvidutide responder analysis at AASLD. How liver stiffness and blood markers differ from the IMPACT trial’s earlier biopsy results.
AI-generated editorial illustration of antibody-testing equipment, not a photograph of the cited studies or a validated instrument design.
Anti-drug antibodies can bind a peptide without proving treatment failure. Learn how neutralization tests, drug exposure and clinical outcomes fit together.
AI-generated editorial illustration of manufacturing equipment, not a photograph of a Samsung or PolyPeptide facility.
Samsung’s PolyPeptide tender passed its acceptance threshold. Why closing remains pending, what the revised timetable says and where factory expansion stands.
AI-generated editorial illustration of laboratory assay equipment, not a photograph of the cited experiment or a validated instrument design.
Learn what IC50, EC50, Kd and Ki measure, why peptide binding can diverge from cellular activity, and what to check before comparing assay numbers.
AI-generated editorial illustration, not a photograph of an actual trial.
Yuviwel’s positive CHMP opinion moves navepegritide toward EU authorization for achondroplasia. What the 52-week growth and safety results establish.
AI-generated editorial illustration, not a photograph of an actual experiment or a validated instrument design.
Albumin can extend peptide circulation through binding and cellular recycling. Three studies explain the measurements, mechanisms and tradeoffs in target activity.
AI-generated editorial illustration, not a photograph of an actual trial.
BMS reports a positive RYZ101 ACTION-1 interim analysis. The population, comparator and progression-free survival endpoint explain what the announcement means.
AI-generated editorial illustration, not a photograph of an actual experiment.
An oxidized peptide peak can arise during mass spectrometry. Three studies explain the methionine mass shift, instrument artifacts and ways to trace the change.
AI-generated editorial illustration
An exploratory SURPASS CVOT analysis favored tirzepatide on a combined death and heart failure outcome. The component results explain its limits.
AI-generated editorial illustration
How SS31 interacts with cardiolipin and mitochondrial proteins, what laboratory experiments reveal, and where the human evidence remains limited.
Viking’s oral VK2735 Phase 3 program pairs trials in adults with and without type 2 diabetes. What the 68 week design measures and the registry says about timing.
The same peptide sequence can behave differently as a TFA, acetate or chloride salt. Three primary studies show why the assay determines the comparison.
A Cedars-Sinai semaglutide study found better heart filling in rats and minipigs without significant weight loss. How it differs from human HFpEF evidence.
Peptides can share an intact mass while their disulfide bonds connect different cysteines. Three cone-snail studies explain how researchers tell them apart.
A 39-person GLP-1 withdrawal pilot found less weight regain with meals or Noom. The four-month results, trial endpoints and funding explain its limits.
Peptide deamidation adds about 0.984 daltons but can also form isoaspartate. Model experiments explain the chemistry and why mass alone can miss it.
Entera's planned EB613 phase 3 trial would test hip bone density. What the oral osteoporosis peptide's earlier study and FDA surrogate endpoint mean.
Peptide aggregation changes more than a fluorescence curve. Experiments show how starting aggregates, dye concentration and measurement choices affect results.
Federal agents searched an Apex-linked warehouse on September 23. The next day, KCAU reported a temporary closure notice on Apex Peptides’ website.
Read full article →
Federal prosecutors announced one year of probation and $180,000 forfeiture in a SARMs and SERMs case involving misleading labels and sales proceeds.
After the September 23 searches, KCAU reported a temporary closure notice and nearly empty Apex Peptides catalog the next day.
Peptide Sciences says it voluntarily shut down research-product sales. Its notice disavows claimed successors but does not identify a government-ordered closure.
PeptideExaminer reports a June 2025 Amino Asylum raid and shutdown, without an identified agency case document; Paradigm Peptides is a separate case.
The DOJ records Matthew Kawa's July 30, 2026 sentence of 70 months, a separate $5 million judgment and a case-specific victim-witness process.
Lilly's TOGETHER-PsO biomarker results offer clues to Taltz and Zepbound's psoriasis response. How the blood findings compare with the clinical trial.
Why peptide cyclization can resist enzymes without guaranteeing cell entry. Bench studies show how ring chemistry, shape and membrane damage change the answer.
REMODEL studied semaglutide in 106 people, including 33 in a kidney biopsy group. Main MRI tests were negative; vessel and gene signals offer clues.
Amylin vs GLP-1: amylin is a hormone released with insulin, GLP-1 is a gut hormone. How amylin analogs such as cagrilintide differ from GLP-1 drugs and what trials show.
J&J reports psoriasis follow-up through week 112. What the original randomized trial showed, why body site matters, and how to read the longer-term results.
D and L amino acids can give a peptide different receptor preferences without changing its mass. What animal peptide experiments reveal about chirality.
Lilly's 48 week trial compared EloraTZP with tirzepatide alone. Greater average weight loss came with more adverse-event withdrawals and an important analysis assumption.
Laboratory studies show why bacterial fragments can remain after filtration and how an endotoxin assay can miss material that still activates immune cells.
A real laboratory comparison shows how water, counterions and a hidden structural impurity change the amount of peptide assigned to a sample.
FDA plans to review five substances before the end of February 2027. The meeting day remains unspecified in its early announcement. How the agenda, GHK-Cu category history and compounding process fit together.
The FDA revised Import Alert 66-80 on September 21, expanding its detention authority to new peptide product codes and adding orforglipron to the Green List. The August revision also disclosed that a Chinese manufacturer allegedly relabeled unapproved semaglutide API from an unlisted facility and altered records.
An FDA advisory panel recommended six peptides for the compounding list over staff objections. What the vote means for rulemaking, patient-specific prescriptions and research use.
Copper peptide studies measure different things: collagen production in cells, ulcer closure, skin changes after laser resurfacing and hair outcomes with a combination treatment. A guide to the results and their limits.
KPV is a three-amino-acid fragment of alpha-MSH with a credible preclinical record in colitis models and wound biology. When the FDA reviewed it in July 2026, staff found no human trial data sufficient to establish effectiveness for its nominated uses.
All three doses met primary endpoints in 2,339 adults. At 12 mg, 45.3% of participants lost at least 30% of body weight by week 80. What the trial data establishes and what comes next.
On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list permanently. What the rule targets, how it differs from the RUO letters, and what remains open.
MOTS-c is encoded not by nuclear DNA but by the mitochondrial genome itself. Rodent studies show it activates AMPK through the folate-AICAR pathway, improving insulin sensitivity. A 2025 paper found it reduced beta-cell senescence in diabetes mice. Human data remains limited.
The 447 participant trial reported lower blood sugar and body weight. The public summary leaves the placebo comparison and endpoint timing unresolved.
Four bench studies trace peptide loss from container walls to distorted calibration curves, with different results across materials and methods.
The November 2025 inspection, the September 18 letter and the evidence FDA wants for sterile production controls. A warning is not a recall.
Three bench studies distinguish peptide recovery, average instrument signal and measurement variability. None supplies a universal shelf life.
Purity, identity, lot numbers and the lab's name: what each part of a peptide COA tells you, and how to check that the report is real.
FDA's research use only labeling rule addresses in vitro diagnostic products in the laboratory research phase, not all lab products or peptides. FDA looks at intended use beyond the label; its August 2026 warning letters said RUO statements did not change its findings about the named peptide sellers' products.
Eli Lilly filed six federal civil lawsuits in August 2026, four against online research use only peptide sellers. One case was voluntarily dismissed on September 2; the others require separate docket checks.
FDA sent August 2026 warning letters to online peptide sellers, including Peptide Partners LLC and Royal Peptides LLC. What the letters allege and why an RUO label alone did not change FDA’s assessment.
Alabama, Mississippi and South Carolina medical boards told licensed providers in 2026 they may not use research-grade peptides with patients. Ohio's pharmacy board says clinics cannot possess them.
Dated 2026 actions involving Paradigm Peptides and Apex-linked properties, with Peptide Sciences' undated shutdown notice kept separate.
Five editorial checks for a research peptide supplier’s documentation and claims; they do not certify compliance.
Buy 1, Get 1 20% Off
Pick any two research compounds. Take 20% off the lower priced one.
Applied automatically at checkout, no code needed
Claim my 20% off →In every pair, the lower priced item is 20% off after other discounts; accessories excluded. For research use only.
The Peptide Digest is a publication covering peptide research, scientific progress and industry news. We explain new findings and the evidence behind them, alongside the regulatory and market developments shaping peptide science.
Content is for informational purposes only. Nothing here constitutes medical advice or an endorsement of any product.
Editorial standards